Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 17,729 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the transaction, the director now directly owns 1,774,285 shares in the company, valued at $30,322,530.65. The sale was disclosed in a filing with the SEC, which is available through this link.
Immunomedics, Inc. (IMMU) traded down $0.01 on Monday, hitting $17.29. The stock had a trading volume of 1,775,357 shares, compared to its average volume of 2,020,000. The firm has a market cap of $2,630.00, a price-to-earnings ratio of -9.30 and a beta of 1.48. Immunomedics, Inc. has a 12 month low of $5.00 and a 12 month high of $18.93. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20.
Immunomedics (NASDAQ:IMMU) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.90 million. equities analysts anticipate that Immunomedics, Inc. will post -0.96 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Immunomedics by 11.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares in the last quarter. Calton & Associates Inc. acquired a new stake in Immunomedics in the fourth quarter valued at about $135,000. Xact Kapitalforvaltning AB acquired a new stake in Immunomedics in the fourth quarter valued at about $193,000. Sapphire Star Partners LP acquired a new stake in Immunomedics in the fourth quarter valued at about $323,000. Finally, SG Americas Securities LLC boosted its stake in Immunomedics by 27.2% in the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 5,631 shares in the last quarter. 74.52% of the stock is currently owned by institutional investors.
WARNING: “Immunomedics, Inc. (IMMU) Director Sells $302,988.61 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/12/immunomedics-inc-immu-director-sells-302988-61-in-stock.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.